Autoantibodies against endothelin 1 Type A receptor are strong predictors of digital ulcers in systemic sclerosis

Journal of Rheumatology

Volumn 42, Issue 10, 2015, Pages 1801-1807

  Avouac, Jérôme ^a,b   Riemekasten, Gabriela ^c   Meune, Christophe ^d,e   Ruiz, Barbara ^a,b   Kahan, André ^a   Allanore, Yannick ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT COCHIN   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITÉ PARIS 13   (France)

^e UMR 942   (France)

Author keywords

Autoantibodies; Biomarker; Digital ulcers; Systemic sclerosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II TYPE 1 RECEPTOR AUTOANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CENTROMERE ANTIBODY; CREATININE; ENDOTHELIN 1; ENDOTHELIN 1 TYPE A RECEPTOR AUTOANTIBODY; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; BIOLOGICAL MARKER; ENDOTHELIN A RECEPTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FORCED VITAL CAPACITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG ARTERY PRESSURE; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE; RECEIVER OPERATING CHARACTERISTIC; SYSTEMIC SCLEROSIS; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; BLOOD; DISEASE COURSE; FINGER; FRANCE; IMMUNOLOGY; INCIDENCE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX RATIO; SKIN ULCER; VASCULARIZATION;

AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; AUTOANTIBODIES; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FINGERS; FRANCE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, ENDOTHELIN A; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SKIN ULCER;

EID: 84943228302     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150061     Document Type: Article

References (21)

1. Allanore Y, Avouac J, Wipff J, Kahan A. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007;8:607-15.
2. Avouac J, Cagnard N, Distler JH, Schoindre Y, Ruiz B, Couraud PO, et al. Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells. Arthritis Rheum 2011;63:3552-62.
3. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010;37:1488-501.
4. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
5. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70:32-8.
6. Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007;34:2423-30.
7. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al; EUSTAR co-authors. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218-21.
8. Avouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010;37:2290-8.
9. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
10. Avouac J, Meune C, Ruiz B, Couraud PO, Uzan G, Boileau C, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis 2012;71:394-9.
11. Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011;70:530-6.
12. Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014;16:R29.
13. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
14. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33:1256-63.
15. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
16. Avouac J, Juin F, Wipff J, Couraud PO, Chiocchia G, Kahan A, et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 2008;67:1455-60.
17. Distler JH, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F, et al; EULAR Scleroderma Trials and Research group. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis 2009;68:163-8.
18. Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, et al; the EUSTAR collaborators. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2014 Aug 27 (E-pub ahead of print).
19. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004;50:216-26.
20. Somhegyi A, Balogh Z, Kormendy M, Gomor B. [Severe diffuse scleroderma in a child]. [Article in Hungarian] Orv Hetil 1987;128:841-4.
21. Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 2014;190:808-17.